Detail akcie Asia Cannabis Rg online

Business Summary: Asia Green Biotechnology Corp. is a Canada-based early-stage international agro-technology company. The Company is focused on the development, evaluation, testing, application and, ultimately, supply to the market of organic hybridization technology and certain products derived from that technology (the Technology). The Company is engaged in planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of the license agreement with InPlanta Biotechnology Inc. (InPlanta) and the evaluation and development of medicinal and related cannabinoid extracts under the terms of license agreements with Swysh Inc. (Swysh), and Pathway Rx Corp (Pathway Rx).
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Asia Green Biotechnology Corp revenues was not reported. Net loss increased from C$68K to C$197K. Higher net loss reflects Consulting fees increase from C$0K to C$105K (expense), Audit and legal fees increase from C$20K to C$42K (expense), Interest increase of 9% to C$25K (expense). Basic Earnings per Share excluding Extraordinary Items totaled to -C$0.01.